Hemodynamic effects of intravenous prenalterol in patients on long-term digoxin therapy for congestive heart failure. 1982

U Dahlström, and E Karlsson, and B Wranne

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011217 Practolol A beta-1 adrenergic antagonist that has been used in the emergency treatment of CARDIAC ARRYTHMIAS. Dalzic,Eralzdin Practolol,ICI-50172,ICI 50172,ICI50172,Practolol, Eralzdin
D011294 Prenalterol A partial adrenergic agonist with functional beta 1-receptor specificity and inotropic effect. It is effective in the treatment of acute CARDIAC FAILURE, postmyocardial infarction low-output syndrome, SHOCK, and reducing ORTHOSTATIC HYPOTENSION in the SHY-RAGER SYNDROME. A-Ba-C-50,005,H-133-22,H-80-62,KWD-2033,Prenalterol Hydrochloride,A Ba C 50,005,ABaC50,005,H13322,H8062,Hydrochloride, Prenalterol,KWD2033
D012146 Rest Freedom from activity. Rests
D002302 Cardiac Output The volume of BLOOD passing through the HEART per unit of time. It is usually expressed as liters (volume) per minute so as not to be confused with STROKE VOLUME (volume per beat). Cardiac Outputs,Output, Cardiac,Outputs, Cardiac
D002316 Cardiotonic Agents Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). Cardiac Stimulant,Cardiac Stimulants,Cardioprotective Agent,Cardioprotective Agents,Cardiotonic,Cardiotonic Agent,Cardiotonic Drug,Inotropic Agents, Positive Cardiac,Myocardial Stimulant,Myocardial Stimulants,Cardiotonic Drugs,Cardiotonics,Agent, Cardioprotective,Agent, Cardiotonic,Drug, Cardiotonic,Stimulant, Cardiac,Stimulant, Myocardial
D004077 Digoxin A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666) Digacin,Digitek,Digoregen,Digoxina Boehringer,Digoxine Nativelle,Dilanacin,Hemigoxine Nativelle,Lanacordin,Lanicor,Lanoxicaps,Lanoxin,Lanoxin-PG,Lenoxin,Mapluxin,Boehringer, Digoxina,Lanoxin PG,Nativelle, Digoxine,Nativelle, Hemigoxine
D005082 Physical Exertion Expenditure of energy during PHYSICAL ACTIVITY. Intensity of exertion may be measured by rate of OXYGEN CONSUMPTION; HEAT produced, or HEART RATE. Perceived exertion, a psychological measure of exertion, is included. Physical Effort,Effort, Physical,Efforts, Physical,Exertion, Physical,Exertions, Physical,Physical Efforts,Physical Exertions
D005260 Female Females

Related Publications

U Dahlström, and E Karlsson, and B Wranne
February 1984, Circulation,
U Dahlström, and E Karlsson, and B Wranne
July 1986, Japanese circulation journal,
U Dahlström, and E Karlsson, and B Wranne
March 1981, The American journal of cardiology,
U Dahlström, and E Karlsson, and B Wranne
January 1987, Pharmacotherapy,
U Dahlström, and E Karlsson, and B Wranne
December 1982, European heart journal,
U Dahlström, and E Karlsson, and B Wranne
January 1982, Acta medica Scandinavica. Supplementum,
U Dahlström, and E Karlsson, and B Wranne
September 1980, Clinical pharmacology and therapeutics,
U Dahlström, and E Karlsson, and B Wranne
July 1985, Zeitschrift fur Kardiologie,
U Dahlström, and E Karlsson, and B Wranne
January 1982, Acta medica Scandinavica. Supplementum,
Copied contents to your clipboard!